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Abstract
Background: Breast cancer is the major cause of cancer-related mortality in women. It is thought that quiescent
stem-like cells within solid tumors are responsible for cancer maintenance, progression and eventual metastasis. We
recently reported that the chemokine receptor CCR7, a multi-functional regulator of breast cancer, maintains the
stem-like cell population.
Methods: This study used a combination of molecular and cellular assays on primary mammary tumor cells from
the MMTV-PyMT transgenic mouse with or without CCR7 to examine the signaling crosstalk between CCR7 and
Notch pathways.
Results: We show for the first time that CCR7 functionally intersects with the Notch signaling pathway to regulate
mammary cancer stem-like cells. In this cell subpopulation, CCR7 stimulation activated the Notch signaling pathway,
and deletion of CCR7 significantly reduced the levels of activated cleaved Notch1. Moreover, blocking Notch activity
prevented specific ligand-induced signaling of CCR7 and augmentation of mammary cancer stem-like cell function.
Conclusion: Crosstalk between CCR7 and Notch1 promotes stemness in mammary cancer cells and may ultimately
potentiate mammary tumor progression. Therefore, dual targeting of both the CCR7 receptor and Notch1 signaling
axes may be a potential therapeutic avenue to specifically inhibit the functions of breast cancer stem cells.
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Introduction
Despite significant recent advances in breast cancer
treatment, breast cancer is still the major cause of
cancer-related death in females worldwide. Resistance to
radiation and chemotherapy, together with unpredictable
recrudescence, are the most challenging issues in clinical
practice. Significant evidence has accumulated in recent
years to implicate cancer stem-like cells (CSCs) as the
main perpetuators of cancer recurrence and therapy re-
sistance in mammary and other tumors, as this cell
population exhibits stem cell-like characteristics of self-
renewal, quiescence and the ability to differentiate into
various cell lineages [1, 2]. Therefore, targeting alter-
ations acquired by CSCs in stemness-related signaling
pathways has been proposed as an effective therapeutic
strategy to counteract current treatment shortfalls in
breast cancer management. However, CSC regulatory
mechanisms remain largely undiscovered.
Chemokine receptors and their ligands have been im-
plicated in numerous aspects of breast malignancy [3].
The chemokine receptor CCR7 and its ligands CCL19
and CCL21 have been associated with metastasis, poor
survival, invasion and cell migration in primary tumors
and breast cancer experimental models [4–6]. We have
recently shown that CCR7 regulates stem cell-like activ-
ity in primary mammary tumors in mice and humans
[7], and sought to understand how CCR7-mediated
stemness interacts with and/or is influenced by recog-
nized stem cell-related signaling pathways.
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The Notch pathway is one of the major signaling axes
in embryonic and adult stem cell homeostasis and has a
critical role in regulating proliferation, differentiation,
apoptosis, cell-cell communication and other multiple
functions [8, 9]. Notch receptors are proteolytically
cleaved in a two-step process, releasing the intracellular
domain that translocates to the nucleus and acts as a
transcriptional cofactor for various genes including those
mediating cell fate [10]. A cancer-specific role of the
Notch axis has also been extensively studied in both
solid and blood neoplasms, and numerous inhibitors of
γ-secretase – the enzyme that cleaves and hence acti-
vates Notch signaling — are now being trialed in human
patients as anti-cancer drugs [11, 12]. Notably, Notch
has been reported to play both oncogenic and tumor-
suppressive roles depending on the cell type and tissue
context [10], thus warranting further investigation into
molecular determinants of the tumor-promoting or
tumor-inhibiting arms of this complex, multifaceted
signaling pathway.
Signaling through the Notch axis has been reported
to crosstalk with multiple other pathways including
numerous oncogenic mediators, such as Wnt effectors
[13], the Hedgehog pathway, cytokines, kinases and
growth factors in mammary and other cancers [14,
15]. Of note is the intersection between the epidermal
growth factor receptor (EGFR) system and Notch
pathway that has been proposed as a mechanism for
trastuzumab resistance in HER2-positive tumors, and
thus a route for therapeutic intervention [16]. Effect-
ively, the identification of specific crosstalk networks
of Notch that govern growth and differentiation of
mammary cancer cells may provide new opportunities
for developing effective inhibitors of tumor relapse
and metastasis.
As Notch pathway members have been implicated in
maintenance of stem cell pools within mammary tumors
[17–19], and having previously found that activation of
CCR7-mediated signaling also promotes stemness [7],
we hypothesized that these pathways may interact within
breast CSC pools to enhance and maintain tumor cell
stemness properties. Using the MMTV-PyMT mouse
model, we show here that CCR7 and Notch1 cooperate
and crosstalk within transformed mammary stem cell-
like compartments, indicating that the CCR7-Notch axis




MMTV-PyMT; Ccr7WT (referred to as PyMT-Ccr7WT)
and MMTV-PyMT; Ccr7−/− (referred to as PyMT-
Ccr7−/−) mice on a pure C57BL/6 background were
generated and described previously [7]. The University
of Adelaide institutional animal ethics committee
approved all protocols.
Mammary cell extraction
Mammary epithelial cell extraction was performed as de-
scribed [20]. Briefly, mouse mammary glands/tumors
were dissected, manually dissociated and then digested
in Dulbecco’s modified Eagle’s medium (DMEM, Gibco)
supplemented with 1 mg/ml collagenase, 100U/ml hyal-
uronidase (both from Worthington) and 2% foetal calf
serum for 3 h at 37 °C. Resultant organoids were
digested a further 15 min with 6U/ml dispase (Gibco)
and 12U/ml DNase I (Merck) at 37 °C. Cells were
filtered through a 70 μm nylon mesh to obtain a single
cell suspension.
Mammosphere culture
Mammosphere cultures were established by seeding
freshly extracted mammary cells in complete sphere
medium (1:1 volumes of DMEM and Ham’s F12
nutrient mix (Gibco) supplemented with 1× B27
(Invitrogen), 10 ng/ml epidermal growth factor (R & D
Systems), 20 ng/ml basic fibroblast growth factor (R &
D Systems), 4 ng/ml heparin (Sigma Aldrich), and 1%
penicillin-streptomycin) to polyhema-coated plates.
After 7 days, mammospheres were passaged by centri-
fuging at 200xg for 5 min, resuspended in trypsin/
EDTA and triturated through a 19G needle to break up
colonies. Cells were filtered through 70 μm and washed
extensively before re-seeding for secondary culture in
complete sphere medium. For all assays, secondary
cultures were analyzed. Where specified, spheres were
cultured in the presence of γ-secretase inhibitor
RO4929097 (SelleckChem) at 50nM, Wnt/β-catenin
inhibitor XAV-939 (SelleckChem) at 1 μM, CCL19 at
200 ng/ml, and CCL21 at 10 ng/ml. For analysis of
mammosphere-forming efficiency, secondary spheres
were assessed for number of spheres formed per cells
seeded.
Flow cytometry and FACS
Flow cytometry/FACS was carried out by blocking for
non-specific binding for 15 min at room temperature in
mouse γ-globulin in PBS/0.5% bovine serum albumin
(BSA) followed by immunostaining for 30–45 min on
ice in PBS/0.5% BSA. Primary anti-mouse antibodies
used were anti-Notch1ECD-APC, biotinylated anti-
Notch1ICD (eBioscience), anti-CD24-PE, anti-CD29-PE,
anti-CCR7-AlexaFluor647 (BD Biosciences), anti-CD24-
FITC, anti-CD24-PE/Cy5 (Life Technologies), anti-
CD29-FITC, anti-CD29-AlexaFluor647, anti-Jagged1-PE
and anti-DLL1-AlexaFluor647 (BioLegend). For Notch1-
ICD, cells were permeabilized prior to labelling followed
by detection using streptavidin-AlexaFluor488 (BD
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Biosciences) in PBS/0.5% BSA for 30 min on ice.
Fluorescence-minus-one (FMO) controls for each anti-
gen in multi-color analysis were used for negative gating.
MFI =mean fluorescence intensity.
Western analysis
Proteins were separated by 10% SDS-PAGE and immobi-
lized onto nitrocellulose membrane. Western analysis was
performed as previously described [21]. The γ-secretase
inhibitor RO4929097 (SelleckChem) was used at 50nM
and CCL19 at 200 ng/ml and times of treatment are speci-
fied in the figures and figure legends. Primary antibodies
used were anti-Notch1 ICD (Abcam), anti-Hes1 (R & D
Systems), anti-phospho-ERK, anti-ERK1/2 (both from Cell
Signaling Technology) and anti-β-Actin (Sigma-Aldrich).
Band intensities were calculated using Image J.
Cyclic AMP analysis
cAMP levels were measured using an AlphaScreen
cAMP Assay Kit (Perkin-Elmer) as per manufacturer’s
instructions. The γ-secretase inhibitor RO4929097 (Sell-
eckChem) was used at 50nM, CCL19 at 200 ng/ml, and
CCL21 at 10 ng/ml. Cells were treated for 30 min before
analysis.
mRNA analysis
Total RNA was extracted using an RNeasy Kit (Qiagen)
and reverse-transcribed using the Transcriptor First
Strand Kit (Roche), followed by quantitative PCR
analysis using the SYBR Green method. Samples were
normalized to endogenous ribosomal protein Rpl32.
qPCR primer sequences are as follows:
Statistics
Data are mean ± SEM and results are representative of
at least 3 independent experiments. Significant statistical
differences were estimated using Student’s t-tests or
ANOVA and significant associations between CCR7 and
Notch1 were identified using Pearson correlation coeffi-
cients. P-values were used to denote statistical signifi-
cance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001.
Results
CCR7 activates the Notch1 signaling pathway in
mammary cancer stem-like cells
In the search for mechanistic clues of the CCR7-
mediated augmentation of the mammary stem cell com-
partment, we investigated crosstalk between CCR7 and
Notch1 pathways, as Notch1 signaling has also been im-
plicated in mammary cancer stem cells [17]. The Notch
intracellular domain is released upon receptor activation
and acts as a transcriptional cofactor to promote stem-
ness [10], therefore we examined the levels of Notch1
receptor domains in the CD24+CD29hi stem cell-
enriched population [22, 23] from PyMT-Ccr7WT and
PyMT-Ccr7−/− murine mammary tumors. The CD24
+CD29hi gating strategy we have employed for all multi-
color flow cytometry throughout the study is shown in
Additional file 1: Figure S1a. While CCR7 did not affect
cell-surface expression of Notch1 (Fig. 1a), levels of the
Notch1 intracellular domain (N1ICD) were significantly
reduced in CCR7-null stem-like cells (Fig. 1b). This find-
ing was substantiated by results obtained in secondary
mammospheres (that are enriched for stem and progeni-
tor cells [24]) from PyMT-Ccr7WT tumors, as stimula-
tion of CCR7 with its ligand CCL19 significantly
increased levels of N1ICD over time (Fig. 1c). Expression
of common Notch ligands DLL1 and Jagged1 was not af-
fected by CCR7 (Additional file 1: Figure S1b and c),
and hence findings were not due to an alteration of
Notch ligands on CSCs, but rather Notch1 itself. Taken
together, these data indicate that Notch1 cleavage is
significantly potentiated by CCR7.
To establish if CCR7-mediated regulation of the Notch
pathway is functional, we tested the levels of Notch tran-
scriptional target Hes1 [10]. Both Hes1 mRNA and pro-
tein levels were significantly reduced in CCR7-null cancer
stem cell-like populations (Fig. 2a and b), either sorted for
CD24+CD29hi expression by FACS or selected through
culturing as secondary mammospheres. Importantly, dir-
ect stimulation of PyMT-Ccr7WT mammospheres through
culturing in the presence of either CCL19 or CCL21
greatly increased Hes1 expression (Fig. 2c), validating re-
sults obtained with the CCR7-null cells. Furthermore,
Hes1 regulation by CCR7-cognate chemokines was recep-
tor specific as it was not seen in PyMT-Ccr7−/− cells
(Fig. 2d). These results suggest that CCR7 regulates ex-
pression of Notch target stemness-promoting genes, and
thus CCR7-mediated functional properties of stemness
may involve Notch pathway activity.
Notch mediates CCR7-promoted stemness in mammary
cancer cells
As Notch activation requires proteolytic cleavage by γ-
secretase, we utilized the γ-secretase inhibitor RO4929097
(previously used in breast cancer studies to inhibit Notch
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signaling [25]) to examine the effect of CCR7 on mam-
mary cancer stem cells in the context of Notch activity
blockade. The effect of RO4929097 in secondary PyMT-
Ccr7WT mammospheres was first verified by examining
Hes1 expression, which was significantly reduced by
addition of the inhibitor (Additional File 1: Figure S2a).
Notably, we found that treatment with RO4929097 did
not affect expression of CCR7 or its ligands CCL19 and
CCL21 (Additional File 1: Figure S2b–d), in contrast with
other studies in leukemic cells [26].
We then assessed the effect of RO4929097 on the
function of CCR7 in mammary stem-like cells. We
found that inhibition of cyclic AMP (cAMP), a read-out
for chemokine receptor activity but not a known out-
come of Notch signaling, was induced by CCL19 and
CCL21; however addition of RO4929097 abrogated this
chemokine-mediated inhibition of forskolin-induced
cAMP (Fig. 3a).
To further confirm that the CCR7 pathway interacts
with Notch signaling, we analyzed mammosphere
growth after addition of CCL19 and CCL21 with and
without RO4929097. We observed that blocking γ-secre-
tase significantly inhibited CCL19-mediated phosphoryl-
ation of ERK, an effector of CCR7 signaling that is not
downstream of Notch itself (Fig. 3b). Notch also affected
the ability of CCR7 to stimulate mammosphere forma-
tion. In concordance with a previous study [27]
RO4929097 reduced secondary mammosphere
formation. The addition of CCL19 or CCL21 was not
sufficient to restore mammosphere formation to levels
seen with chemokine stimulation alone (Fig. 3c),
suggesting that inhibition of Notch inhibits the
stemness-promoting function of CCR7. However, mam-
mosphere formation was partially rescued, indicating
that there are other Notch-independent pathways in play
in this context.
We observed that the other major signaling pathway
previously implicated in stem cell maintenance, Wnt/β-
catenin [28], did not impact upon CCR7-mediated stem-
ness as the Notch pathway appears to. Specifically, while
Fig. 1 Cleavage of Notch1 in mammary cancer stem-like cells is dependent on CCR7. a-b Primary PyMT-Ccr7WT and Ccr7−/− mammary tumor cells
were analyzed by multi-color flow cytometry for Notch1 expression within the stem cell-enriched population CD24+CD29hi. Top = representative flow
cytometry plots, bottom = quantification. a Notch1 extracellular domain (ECD) cell surface expression in the PyMT-Ccr7WT and Ccr7−/− mammary stem
cell-like population. b Notch1 intracellular domain (ICD) levels in the PyMT-Ccr7WT and Ccr7−/− mammary stem cell-like population. Bulk tumor cells
were first labelled for extracellular CD24 and CD29 before permeabilization and staining for Notch1 ICD. a-b n = 4 mice/genotype. FMO = fluorescence
minus one, MFI =mean fluorescence intensity. c Notch1 ICD levels in PyMT-Ccr7WT secondary mammospheres, stimulated with CCL19 for varying
lengths of time as indicated before lysis for Western analysis. n = 6 mice/experiment
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inhibition of Wnt signaling with the specific inhibitor
XAV-939 significantly decreased sphere-forming ability
and hence stemness properties in primary PyMT-
expressing tumor cells as expected [29], addition of the
CCR7 ligand CCL21 to XAV-939 treated cells was suffi-
cient to restore sphere formation to that seen when
stimulated with CCL21 alone (Additional File 1: Figure
S3), thus demonstrating that the Wnt pathway is not in-
volved in CCR7-mediated regulation of stem cell
maintenance.
These data show that the function of CCR7 in promot-
ing the stemness of mammary tumor cells is partly
mediated through Notch signaling. Although CCR7
regulates Notch1 activation in MMTV-PyMT tumor
cells, the two pathways likely cooperate to promote CSC
activity.
Discussion
Despite advances in clinical treatment of breast cancer,
recurrence remains a significant problem due to the sur-
vival of quiescent cancer stem cells. Novel combination
therapies against CSCs, acting as adjuvants together with
conventional approaches, are therefore needed. We pre-
viously demonstrated that the chemokine receptor
CCR7 promotes mammary tumorigenesis via amplifica-
tion of stem-like cells [7], and we now show here that
crosstalk between Notch and CCR7 signaling promotes
breast cancer stemness and may be a potential target for
these new therapies.
Notch can have opposing roles depending on bio-
logical context, with Notch1 activation shown to both
perpetuate and inhibit cell differentiation [10]. Notch
also regulates, and is regulated by, different chemokine
receptors. In acute lymphoblastic leukemia, Notch1 reg-
ulates cell proliferation and migration through CCR5
and CCR9 [30], and in multiple myeloma Notch regu-
lates CXCR4 [31]. While no functional crosstalk between
the two pathways has been reported so far, it was sug-
gested that Notch activation up-regulates CCR7 expres-
sion in leukemic cells [26]. However, in TCR-activated
peripheral blood mononuclear cells CCR7 expression
was slightly increased following Notch inhibition with
RO4929097 [25]. In breast cancer, CCL2 secreted from
cancer-associated fibroblasts induces a CSC phenotype
by activating Notch signaling, highlighting the concept
that crosstalk may exist between the two axes [32].
Plausibly, the interplay between CCR7 and Notch is
adaptable in different systems.
Fig. 2 CCR7 activates the Notch signaling pathway in mammary cancer stem-like cells. a-b Hes1 expression was assessed in primary mammary CSCs
from PyMT-Ccr7WT and Ccr7−/− tumors. a Hes1 mRNA levels relative to PyMT-Ccr7−/− in the sorted CD24+CD29hi stem cell-enriched population (left)
and in secondary mammospheres (right), n = 4–6 mice/genotype/experiment. b Hes1 protein expression in the CD24+CD29hi sorted cell population,
n = 4 mice/genotype. c Relative Hes1 mRNA levels in PyMT-Ccr7WT secondary mammospheres cultured with and without CCL19 and CCL21. d Relative
Hes1 mRNA levels in PyMT-Ccr7−/− secondary mammospheres cultured with and without CCL19. c–d n = 6 mice/experiment
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In this study, we have demonstrated that the dele-
tion of CCR7 significantly decreases levels of acti-
vated Notch1, and conversely, stimulation of the
CCR7 pathway increases Notch receptor activation
and expression of downstream target genes. We did
not find any substantial Notch-mediated regulation
of CCR7 receptor or ligand expression but observed
a significant crosstalk at the functional level, which
was not seen with the other major signaling pathway
involved in stem cell maintenance, Wnt/β-catenin
[28]. Notably, unlike other cellular types such as
lymphocytes that display differential-ligand induced
CCR7 signaling and functional events [33] the
observed CCR7 effect upon stemness is not ligand-
specific, as we observed similar results for both
CCL19 and CCL21.
Fig. 3 Notch promotes CCR7-mediated stemness. a Level of cyclic AMP (cAMP) in PyMT-Ccr7WT mammospheres with and without CCL19 stimulation
and Notch inhibition, determined by an AlphaScreen cAMP assay. Cells were treated with CCL19, CCL21 and RO4029097 for 30 min before analysis. b
PyMT-Ccr7WT secondary mammospheres were tested for phosphorylation of ERK as a read-out for CCR7 activation with and without ligand stimulation
and Notch inhibition. Cells were treated with CCL19 and RO4029097 for 15 min before lysis for Western analysis. c Secondary mammosphere-forming
efficiency (number of spheres/cells seeded) of PyMT-Ccr7WT primary mammary tumor cells cultured with and without chemokines CCL19 and CCL21,
and RO4029097. a–c n = 6 mice/experiment
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Importantly, these findings may be translatable to hu-
man disease, as analysis of a published database available
in Oncomine [34] showed that expression of CCR7 and
Notch1 are significantly correlated in primary human
breast cancers, particularly in higher grade tumors
(Additional File 1: Figure S4). Although Notch proteins
are known to regulate stemness, and CCR7 to promote
tumorigenesis through a number of pathways, to the
best of our knowledge this is the first study linking
Notch1 to CCR7-dependent regulation of stem-like cells
in mammary cancer. This novel phenomenon opens up
the avenue for concurrent therapeutic targeting of these
pathways. Antagonists towards CCR7 are capable of
reducing stem-like cell content and activity [7], and γ-
secretase inhibitors and antibodies that block the Notch
pathway have also been shown to specifically target
tumor-initiating cells [35, 36]. This approach may there-
fore be a new opportunity for targeting evasive cancer
stem cells to control breast cancer progression.
Additional file
Additional file 1: Supplementary Figures. (PDF 17190 kb)
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